{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT04886804","nct_id":"NCT04886804","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04886804. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.","label":"Phase Ia - Dose escalation part","type":"EXPERIMENTAL"},{"description":null,"label":"Phase Ib - Dose expansion part: Cohort 1","type":"EXPERIMENTAL"},{"description":null,"label":"Phase Ib - Dose expansion part: Cohort 2","type":"EXPERIMENTAL"},{"description":null,"label":"Phase Ib - Dose expansion part: Cohort 3","type":"EXPERIMENTAL"},{"description":null,"label":"Phase Ib - Dose expansion part: Cohort 4","type":"EXPERIMENTAL"},{"description":null,"label":"Phase Ib - Dose expansion part: Cohort 5","type":"EXPERIMENTAL"},{"description":"Cohort only in the United States of America (USA)","label":"Phase Ib - Dose expansion part: Cohort 6","type":"EXPERIMENTAL"},{"description":"Cohort only in Japan","label":"Phase Ib - Dose expansion part: Cohort 7","type":"EXPERIMENTAL"},{"description":"Cohort only in the United States of America (USA)","label":"Phase Ib - Dose expansion part: Cohort 8","type":"EXPERIMENTAL"},{"description":"Cohort only in China","label":"Phase Ib - Dose expansion part: Cohort 9","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-08-30","type":"ESTIMATED"},"conditions":["Neoplasm Metastasis","Non-Small Cell Lung Cancer"],"enrollment":{"count":554,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"zongertinib","type":"DRUG"}],"last_update":"2026-10-05","lead_sponsor":"Boehringer Ingelheim","official_title":"Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase Ia: Maximum Tolerated Dose (MTD)","timeFrame":"At the end of Cycle 1 (each cycle is 21 days)."},{"measure":"Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation period","timeFrame":"At the end of Cycle 1 (each cycle is 21 days)."},{"measure":"Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent review","timeFrame":"From the start of the trial treatment until end of month 12, up to 12 months."},{"measure":"Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessment","timeFrame":"From the start of the trial treatment until end of month 12, up to 12 months."},{"measure":"Phase Ib: Cohort 4: Objective response according to Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) by central independent review","timeFrame":"From the start of the trial treatment until end of month 12, up to 12 months."}],"references":[{"citation":"Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, Nadal E, Wu YL, Zugazagoitia J, Tu HY, Baik CS, Yoh K, Soo RA, Zhao Y, Sabari JK, Wermke M, Scheffler M, Ahn MJ, Fernamberg K, Schroeter L, Sadrolhefazi B, Thamer C, Eigenbrod-Giese S, Popat S; Beamion LUNG-1 Investigators. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Apr 30;394(17):1675-1684. doi: 10.1056/NEJMoa2516969. Epub 2026 Apr 15.","pmid":"41985129","type":"DERIVED"},{"citation":"Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28.","pmid":"40293180","type":"DERIVED"},{"citation":"Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schroter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3.","pmid":"40030100","type":"DERIVED"},{"citation":"Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, Yamamoto N. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Clin Lung Cancer. 2023 Mar;24(2):e65-e68. doi: 10.1016/j.cllc.2022.10.008. Epub 2022 Nov 11.","pmid":"36528522","type":"DERIVED"}],"start_date":{"date":"2021-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","url":"https://clinicaltrials.gov/study/NCT04886804"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04886804"}